The new effective drug eluksadolin from companies Furiex Pharmaceuticals

IBS is a rare disease, which is called irritable bowel syndrome.

Clinical trials conducted on the drug 2428 volunteers, by a certain algorithm. They were divided into three groups, and each of them took on a fixed schedule preparation:

• 1 a group of volunteers had to take 75 mg drugs 2 times a day.
• 2 group received an increased dose 100 mg, but only once a day.
• 3 a group of volunteers took a placebo instead of the drug.

The test was conducted in two phases. Combination steel outcome results of the two studies point, In the first case, the results were better than placebo, in the second case, the use of the drug at various doses.

After 12 weeks of preparation by patients, were recorded results, who met all the requirements of FDA. In the first case, compared the results of honey 1 and 3 groups, which was 9,5 %. In the second case, compared the results 2 and 3 groups, he is 10,3 %.

After 26 weeks testing, Research results have been recorded, who met all the requirements of EMA. The test results have been impressive. The difference between the first group (dose 75mg) and topics, who took a placebo was 7,2%. A second group of results between (dose 100 mg) and placebo was 11,5 %.

Test volunteers celebrated, that during use eluksadolina decreased pain, and normalized bowel work. The symptom of diarrhea was observed during treatment. but, some volunteers were shown side effects during the use of the drug. They were accompanied by nausea and frequent constipation.

Company Furiex Pharmaceuticals pleased with the results of tests and has already filed an application for registration of the product. Checks already underway with the FDA 2014 of the year, and begin to consider an application with the EMA 2015 of the year.

All data are from the official press release of the company Furiex Pharmaceuticals.